Follow-up results of a prospective, multicenter, open-label study of oral fludarabine phosphate in patients with previously untreated B-CLL.

被引：0
|
作者：
Rossi, JF
Van Hoof, A
De Boeck, K
Johnson, SA
Bron, D
Foussard, C
Lister, TA
Kramer, MHH
Littlewood, TJ
Marcus, RE
Deconinck, E
Guibon, O
Montillo, M
Tollerfield, SM
机构：
[1] Univ Hosp, Montpellier, France
[2] Acad Hosp St Jan, Brugge, Belgium
[3] Middelheim Hosp, B-2020 Antwerp, Belgium
[4] Musgrove Pk Hosp, Taunton, Somerset, England
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Univ Hosp, Angers, France
[7] St Bartholomews Hosp, London, England
[8] Meander MC, Amersfoort, Netherlands
[9] Oxford Radcliffe NHS Trust, Oxford, England
[10] Addenbrookes Hosp, Cambridge, England
[11] Univ Hosp, Besancon, France
[12] Hop St Louis, Paris, France
[13] Osped Niguarda Ca Granda, Milan, Italy
[14] Schering Hlth Care, Burgess Hill, England
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.2128.2128
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2128
引用
收藏
页码：602A / 602A
页数：1
相关论文
共 50 条
  • [1] Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL:: Final response and follow-up in 75 patients.
    Cazin, BF
    Maloum, K
    Créteil, MD
    Leprêtre, S
    Travade, P
    Delmer, A
    Jaubert, J
    Lederlin, P
    Dreyfus, B
    Leporrier, M
    Harousseau, JL
    Grosbois, B
    Maloisel, F
    Eghbali, H
    Dumontet, C
    Benichou, J
    Guibon, O
    BLOOD, 2003, 102 (11) : 438A - 439A
  • [2] An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
    Chen, Christine
    Paul, Harminder
    Del Rizzo, Luisa
    Le, Lisa W.
    Wei, Ellen Nong
    Lau, Anthea
    Johnston, James B.
    Gibson, Spencer B.
    Brown, Michelle
    Trudel, Suzanne
    BLOOD, 2012, 120 (21)
  • [3] Fixed-Duration Venetoclax-Obinutuzumab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: Follow-Up of Efficacy and Safety Results From the Multicenter, Open-Label, Randomized, Phase III CLL14 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 11 - 11
  • [4] Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
    Al-Sawaf, Othman
    Zhang, Can
    Tandon, Maneesh
    Sinha, Arijit
    Fink, Anna Maria
    Robrecht, Sandra
    Tausch, Eugen
    Schary, William L.
    Ritgen, Matthias
    Wendtner, Clemens Martin
    Kreuzer, Karl A.
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Hallek, Michael J.
    Fischer, Kirsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Open-label prospective study of efficacy and safety of levetiracetam:: One year follow-up
    Villanueva, VE
    Gutiérrez-Delicado, E
    Caicoya, AG
    Serratosa, JM
    EPILEPSIA, 2005, 46 : 270 - 270
  • [6] Efficacy and response duration of oral fludarabine phosphate (Flu) in 81 previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL): Update of the european multicenter study.
    Rossi, JF
    Van Hoof, A
    De Bock, R
    Johnson, SA
    Bron, D
    Foussard, C
    Lister, TA
    Berthou, C
    Kramer, MHH
    Littlewood, TJ
    Marcus, RE
    Deconninck, E
    Montillo, M
    Benitez, O
    Bloomfield, R
    BLOOD, 2003, 102 (11) : 672A - 673A
  • [7] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study
    Sidonio, Robert F.
    Thompson, Alexis A.
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Antmen, Ali Bulent
    Maggiore, Caterina
    Engl, Werner
    Ewenstein, Bruce
    Tangada, Srilatha
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (10) : 793 - 801
  • [8] Inhibitor development in previously untreated patients with hemophilia A and B: A prospective 23-year follow-up
    Ettingshausen, CE
    Zyschka, A
    Oldenburg, J
    Saguer, IM
    Ehrenforth, S
    Kreuz, W
    30TH HEMOPHILIA SYMPOSIUM, 2001, : 110 - 113
  • [9] A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
    Arellano, Martha L.
    Borthakur, Gautam
    Berger, Mark
    Luer, Jill
    Raza, Azra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06): : 534 - 539
  • [10] The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study
    Ahn, Yong Min
    Lee, Kyu Young
    Kim, Chul-Eung
    Kang, Dae-Yeob
    Seok, Jeong-Ho
    Shin, Young Min
    Chung, In-Won
    Jun, Tae-Youn
    Chang, Jae Seung
    Kim, Yong Sik
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (08) : 568 - 577
12345